Cartesian Therapeutics (RNAC) Current Taxes (2021 - 2022)

Cartesian Therapeutics' (RNAC) quarterly Current Taxes came in at $320000.0 in Q2 2022, little changed on a QoQ basis from $320000.0 in Q1 2022.

Cartesian Therapeutics (RNAC) Current Taxes (2021 - 2022) Analysis & Trends

Cartesian Therapeutics (RNAC) has 2 years of Current Taxes data on file, last reported at $320000.0 in Q2 2022.

On a quarterly basis, Current Taxes changed N/A year-over-year to $320000.0 in Q2 2022; TTM through Jun 2022 was $320000.0, a N/A change from a year earlier, with the FY2021 full-year figure at $601000.0, changed N/A from the prior year.
Current Taxes for Q2 2022 stood at $320000.0, roughly flat from $320000.0 in the prior quarter.
Over the last five years, Current Taxes for RNAC reached as high as $15.8 million in Q3 2021 and fell as low as $320000.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Taxes (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	63.52 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Cartesian Therapeutics	210.28 Mn	210.28 Mn	-	-

Download Data